Biogen (BIIB) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Biogen (NASDAQ: BIIB) recently:

  • 1/5/2018 – Biogen was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/2/2018 – Biogen had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 12/30/2017 – Biogen had its price target raised by analysts at Nomura from $355.00 to $420.00. They now have a “buy” rating on the stock.
  • 12/22/2017 – Biogen had its price target raised by analysts at Nomura from $355.00 to $420.00. They now have a “buy” rating on the stock.
  • 12/21/2017 – Biogen was given a new $400.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 12/20/2017 – Biogen was given a new $340.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.
  • 12/20/2017 – Biogen was upgraded by analysts at Credit Suisse Group AG from a “neutral” rating to an “outperform” rating. They now have a $385.00 price target on the stock, up previously from $321.00.
  • 12/18/2017 – Biogen had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $390.00 price target on the stock.
  • 12/5/2017 – Biogen had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $321.00 price target on the stock.
  • 12/4/2017 – Biogen was given a new $350.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/28/2017 – Biogen was given a new $350.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/28/2017 – Biogen was given a new $318.00 price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 11/27/2017 – Biogen had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $338.00 price target on the stock.
  • 11/27/2017 – Biogen had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $385.00 price target on the stock.
  • 11/27/2017 – Biogen was given a new $378.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 11/27/2017 – Biogen was given a new $400.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 11/22/2017 – Biogen had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $350.00 price target on the stock.
  • 11/13/2017 – Biogen was given a new $400.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 11/9/2017 – Biogen is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $350.00 price target on the stock.
  • 11/6/2017 – Biogen had its price target raised by analysts at BMO Capital Markets from $381.00 to $386.00. They now have an “outperform” rating on the stock.

Shares of Biogen Inc (BIIB) traded up $0.14 during mid-day trading on Friday, hitting $339.99. The stock had a trading volume of 967,000 shares, compared to its average volume of 1,170,400. The firm has a market cap of $71,990.00, a PE ratio of 20.85, a PEG ratio of 1.95 and a beta of 0.73. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46. Biogen Inc has a fifty-two week low of $244.28 and a fifty-two week high of $348.84.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $5.70 by $0.61. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.19 EPS. research analysts expect that Biogen Inc will post 21.98 EPS for the current year.

In related news, CEO Michel Vounatsos acquired 780 shares of the firm’s stock in a transaction dated Friday, December 29th. The stock was acquired at an average price of $320.55 per share, with a total value of $250,029.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Alexander J. Denner purchased 30,000 shares of Biogen stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average cost of $317.36 per share, with a total value of $9,520,800.00. Following the acquisition, the director now directly owns 10,029 shares in the company, valued at approximately $3,182,803.44. The disclosure for this purchase can be found here. In the last three months, insiders bought 31,560 shares of company stock valued at $10,020,858. Insiders own 0.25% of the company’s stock.

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply